Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 305

1.

Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa.

Pogue JM, Kaye KS, Veve MP, Patel TS, Gerlach AT, Davis SL, Puzniak LA, File TM, Olson S, Dhar S, Bonomo RA, Perez F.

Clin Infect Dis. 2019 Sep 23. pii: ciz816. doi: 10.1093/cid/ciz816. [Epub ahead of print]

PMID:
31545346
2.

Risk Factors and Outcomes Associated With Treatment of Asymptomatic Bacteriuria in Hospitalized Patients.

Petty LA, Vaughn VM, Flanders SA, Malani AN, Conlon A, Kaye KS, Thyagarajan R, Osterholzer D, Nielsen D, Eschenauer GA, Bloemers S, McLaughlin E, Gandhi TN.

JAMA Intern Med. 2019 Aug 26. doi: 10.1001/jamainternmed.2019.2871. [Epub ahead of print]

PMID:
31449295
3.

A multicenter study of the real-world use of ceftaroline versus vancomycin for acute bacterial skin and skin structure infections.

Trinh TD, Jorgensen SCJ, Zasowski EJ, Claeys KC, Lagnf AM, Estrada SJ, Delaportes DJ, Huang V, Klinker KP, Kaye KS, Davis SL, Rybak MJ.

Antimicrob Agents Chemother. 2019 Aug 12. pii: AAC.01007-19. doi: 10.1128/AAC.01007-19. [Epub ahead of print]

PMID:
31405859
4.

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.

Motsch J, Murta de Oliveira C, Stus V, Köksal I, Lyulko O, Boucher HW, Kaye KS, File TM, Brown ML, Khan I, Du J, Joeng HK, Tipping RW, Aggrey A, Young K, Kartsonis NA, Butterton JR, Paschke A.

Clin Infect Dis. 2019 Aug 10. pii: ciz530. doi: 10.1093/cid/ciz530. [Epub ahead of print]

PMID:
31400759
5.

Use of Colistin in Critically Ill Patients.

Marchaim D, Kaye D, Kaye KS.

Adv Exp Med Biol. 2019;1145:155-179. doi: 10.1007/978-3-030-16373-0_12. Review.

PMID:
31364078
6.

Identification of four patients with colistin-resistant Escherichia coli containing the mobile colistin resistance mcr-1 gene from a single health system in Michigan.

Henig O, Rojas LJ, Bachman MA, Rudin SD, Brennan BM, Soehnlen MK, Jones KL, Mills JP, Dombecki CR, Valyko AM, Marshall SH, Bonomo RA, Kaye KS, Washer L.

Infect Control Hosp Epidemiol. 2019 Sep;40(9):1059-1062. doi: 10.1017/ice.2019.177. Epub 2019 Jul 15.

PMID:
31303191
7.

Risk factors for endemic Acinetobacter Baumannii colonization: A case-case study.

Thorne A, Luo T, Durairajan NK, Kaye KS, Foxman B.

Am J Infect Control. 2019 Jun 25. pii: S0196-6553(19)30462-6. doi: 10.1016/j.ajic.2019.04.179. [Epub ahead of print]

PMID:
31253551
8.

The Pitt Bacteremia Score Predicts Mortality in Non-Bacteremic Infections.

Henderson H, Luterbach CL, Cober E, Richter SS, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Evans S, Fowler VG, Bonomo RA, Harris A, Napravnik S, van Duin D.

Clin Infect Dis. 2019 Jun 19. pii: ciz528. doi: 10.1093/cid/ciz528. [Epub ahead of print]

PMID:
31219148
9.

Vancomycin-Resistant Enterococcus Acquisition in a Tertiary Care Hospital: Testing the Roles of Antibiotic Use, Proton Pump Inhibitor Use, and Colonization Pressure.

Chanderraj R, Millar JA, Patel TS, Read AF, Washer L, Kaye KS, Woods RJ.

Open Forum Infect Dis. 2019 Mar 15;6(4):ofz139. doi: 10.1093/ofid/ofz139. eCollection 2019 Apr.

10.

Implementation and Impact of an Antimicrobial Stewardship Program at a Tertiary Care Center in South India.

Singh S, Menon VP, Mohamed ZU, Kumar VA, Nampoothiri V, Sudhir S, Moni M, Dipu TS, Dutt A, Edathadathil F, Keerthivasan G, Kaye KS, Patel PK.

Open Forum Infect Dis. 2018 Nov 8;6(4):ofy290. doi: 10.1093/ofid/ofy290. eCollection 2019 Apr.

11.

Shifting Gears: The Future of Polymyxin Antibiotics.

Lenhard JR, Bulman ZP, Tsuji BT, Kaye KS.

Antibiotics (Basel). 2019 Apr 12;8(2). pii: E42. doi: 10.3390/antibiotics8020042. Review.

12.

Multidrug-resistant Organisms in Hospitals: What Is on Patient Hands and in Their Rooms?

Mody L, Washer LL, Kaye KS, Gibson K, Saint S, Reyes K, Cassone M, Mantey J, Cao J, Altamimi S, Perri M, Sax H, Chopra V, Zervos M.

Clin Infect Dis. 2019 Apr 13. pii: ciz092. doi: 10.1093/cid/ciz092. [Epub ahead of print]

PMID:
30980082
13.

Current Epidemiology, Etiology, and Burden of Acute Skin Infections in the United States.

Kaye KS, Petty LA, Shorr AF, Zilberberg MD.

Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S193-S199. doi: 10.1093/cid/ciz002.

14.

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus.

Claeys KC, Zasowski EJ, Trinh TD, Casapao AM, Pogue JM, Bhatia N, Mynatt RP, Wilson SS, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado G, Giuliano CA, Takla R, Rieck C, Johnson LB, Murray KP, Gordon J, Reyes K, Hartman P, Davis SL, Rybak MJ.

Infect Dis Ther. 2019 Jun;8(2):199-208. doi: 10.1007/s40121-019-0242-5. Epub 2019 Mar 27.

15.

Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP): ZEUS, A Phase 2/3 Randomized Trial.

Kaye KS, Rice LB, Dane A, Stus V, Sagan O, Fedosiuk E, Das A, Skarinsky D, Eckburg PB, Ellis-Grosse EJ.

Clin Infect Dis. 2019 Mar 6. pii: ciz181. doi: 10.1093/cid/ciz181. [Epub ahead of print]

PMID:
30861061
16.

Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience.

Destache CJ, Guervil DJ, Kaye KS.

Int J Antimicrob Agents. 2019 May;53(5):644-649. doi: 10.1016/j.ijantimicag.2019.01.014. Epub 2019 Jan 31.

17.
18.

The hypothetical impact of Accelerate Pheno™ system on time to effective therapy and time to definitive therapy in an institution with an established antimicrobial stewardship programme currently utilizing rapid genotypic organism/resistance marker identification.

Henig O, Cooper CC, Kaye KS, Lephart P, Salimnia H, Taylor M, Hussain N, Hussain Z, Deeds K, Hayat U, Patel J, Pogue JM.

J Antimicrob Chemother. 2019 Jan 1;74(Supplement_1):i32-i39. doi: 10.1093/jac/dky533.

19.

The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae.

Luterbach CL, Boshe A, Henderson HI, Cober E, Richter SS, Salata RA, Kalayjian RC, Watkins RR, Hujer AM, Hujer KM, Rudin SD, Domitrovic TN, Doi Y, Kaye KS, Evans S, Fowler VG Jr, Bonomo RA, van Duin D.

Open Forum Infect Dis. 2018 Dec 14;6(1):ofy351. doi: 10.1093/ofid/ofy351. eCollection 2019 Jan.

20.

The Hypothetical Impact of Accelerate Pheno on Time to Effective Therapy and Time to Definitive Therapy for Bloodstream Infections Due to Drug-Resistant Gram-Negative Bacilli.

Henig O, Kaye KS, Chandramohan S, Cooper CC, Lephart P, Salimnia H, Taylor M, Pogue JM.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01477-18. doi: 10.1128/AAC.01477-18. Print 2019 Mar.

21.

Training infection prevention leaders for the present and future: United in patient safety.

Kaye KS, Haas J.

Am J Infect Control. 2018 Dec;46(12):1320-1321. doi: 10.1016/j.ajic.2018.08.023. No abstract available.

PMID:
30502755
22.

It is time to define antimicrobial never events.

Liu J, Kaye KS, Mercuro NJ, Davis SL, Patel TS, Petty LA, Pais GM, Scheetz MH.

Infect Control Hosp Epidemiol. 2019 Feb;40(2):206-207. doi: 10.1017/ice.2018.313. Epub 2018 Dec 5.

PMID:
30516126
23.

An update on antimicrobial resistance and the role of newer antimicrobial agents for Pseudomonas aeruginosa.

Pragasam AK, Veeraraghavan B, Nalini E, Anandan S, Kaye KS.

Indian J Med Microbiol. 2018 Jul-Sep;36(3):303-316. doi: 10.4103/ijmm.IJMM_18_334. Review.

24.

Pseudomonas aeruginosa - Difficult to outmanoeuvre.

Patel PK, Patel TS, Kaye KS.

Indian J Med Microbiol. 2018 Jul-Sep;36(3):301-302. doi: 10.4103/ijmm.IJMM_18_331. No abstract available.

25.

Epidemiology of Diabetic Foot Infection in the Metro-Detroit Area With a Focus on Independent Predictors for Pathogens Resistant to Recommended Empiric Antimicrobial Therapy.

Henig O, Pogue JM, Cha R, Kilgore PE, Hayat U, Ja'ara M, Ali RM, Mahboob S, Pansare R, Deeds K, Joarder B, Kandala H, Dhar S, Kaye KS.

Open Forum Infect Dis. 2018 Sep 27;5(11):ofy245. doi: 10.1093/ofid/ofy245. eCollection 2018 Nov.

26.

Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility.

Almangour TA, Perry GK, Terriff CM, Alhifany AA, Kaye KS.

Diagn Microbiol Infect Dis. 2019 Mar;93(3):213-218. doi: 10.1016/j.diagmicrobio.2018.10.007. Epub 2018 Oct 16.

PMID:
30396697
27.

Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.

Albin OR, Patel TS, Kaye KS.

Expert Rev Anti Infect Ther. 2018 Dec;16(12):865-876. doi: 10.1080/14787210.2018.1542300. Epub 2018 Nov 5. Review.

PMID:
30372359
28.

Epidemiology of Carbapenem-Resistant Enterobacteriaceae at a Long-term Acute Care Hospital.

Chopra T, Rivard C, Awali RA, Krishna A, Bonomo RA, Perez F, Kaye KS.

Open Forum Infect Dis. 2018 Oct 3;5(10):ofy224. doi: 10.1093/ofid/ofy224. eCollection 2018 Oct.

29.

Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.

Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS.

Infect Dis Ther. 2018 Dec;7(4):439-455. doi: 10.1007/s40121-018-0214-1. Epub 2018 Oct 1.

30.

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae.

Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS.

Infect Drug Resist. 2018 Sep 12;11:1461-1472. doi: 10.2147/IDR.S150447. eCollection 2018. Review.

31.

The epidemiological impact and significance of carbapenem resistance in Pseudomonas aeruginosa bloodstream infections: a matched case-case-control analysis.

Aviv T, Lazarovitch T, Katz D, Zaidenstein R, Dadon M, Daniel C, Tal-Jasper R, Kaye KS, Marchaim D.

Infect Control Hosp Epidemiol. 2018 Oct;39(10):1262-1265. doi: 10.1017/ice.2018.181. Epub 2018 Aug 14.

PMID:
30103833
32.

Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations.

Pogue JM, Bonomo RA, Kaye KS.

Clin Infect Dis. 2019 Jan 18;68(3):519-524. doi: 10.1093/cid/ciy576.

PMID:
30020449
33.

Towards a Definition for Health Care-Associated Infection.

Friedman ND, Levit D, Taleb E, Marcus G, Michaeli L, Broide M, Mengesha B, Zaidenstein R, Lazarovitch T, Dadon M, Kaye KS, Marchaim D.

Open Forum Infect Dis. 2018 May 23;5(6):ofy116. doi: 10.1093/ofid/ofy116. eCollection 2018 Jun 1.

34.

Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model.

Barber KE, Pogue JM, Warnock HD, Bonomo RA, Kaye KS.

J Antimicrob Chemother. 2018 Sep 1;73(9):2405-2410. doi: 10.1093/jac/dky213.

PMID:
29939267
35.

Comparison of the composition and in vitro activity of polymyxin B products.

Diep JK, Covelli J, Sharma R, Ruszaj DM, Kaye KS, Li J, Straubinger RM, Rao GG.

Int J Antimicrob Agents. 2018 Sep;52(3):365-371. doi: 10.1016/j.ijantimicag.2018.05.014. Epub 2018 May 25.

PMID:
29807163
36.

Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm.

Lakota EA, Landersdorfer CB, Nation RL, Li J, Kaye KS, Rao GG, Forrest A.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00483-18. doi: 10.1128/AAC.00483-18. Print 2018 Jul.

37.

Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.

Patel TS, Pogue JM, Mills JP, Kaye KS.

Future Microbiol. 2018 Jul;13:971-983. doi: 10.2217/fmb-2018-0054. Epub 2018 Apr 25.

38.

Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.

Papp-Wallace KM, Barnes MD, Alsop J, Taracila MA, Bethel CR, Becka SA, van Duin D, Kreiswirth BN, Kaye KS, Bonomo RA.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00174-18. doi: 10.1128/AAC.00174-18. Print 2018 Jun.

39.

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.

Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, Vazquez J, Zaitsev V, Bidair M, Chorvat E, Dragoescu PO, Fedosiuk E, Horcajada JP, Murta C, Sarychev Y, Stoev V, Morgan E, Fusaro K, Griffith D, Lomovskaya O, Alexander EL, Loutit J, Dudley MN, Giamarellos-Bourboulis EJ.

JAMA. 2018 Feb 27;319(8):788-799. doi: 10.1001/jama.2018.0438.

40.

Evaluation of Sensititre Broth Microdilution Plate for determining the susceptibility of carbapenem-resistant Klebsiella pneumoniae to polymyxins.

Richter SS, Karichu J, Otiso J, Van Heule H, Keller G, Cober E, Rojas LJ, Hujer AM, Hujer KM, Marshall S, Perez F, Rudin SD, Domitrovic TN, Kaye KS, Salata R, van Duin D, Bonomo RA.

Diagn Microbiol Infect Dis. 2018 May;91(1):89-92. doi: 10.1016/j.diagmicrobio.2018.01.005. Epub 2018 Jan 9.

41.

Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals.

Papst L, Beović B, Pulcini C, Durante-Mangoni E, Rodríguez-Baño J, Kaye KS, Daikos GL, Raka L, Paul M; ESGAP, ESGBIS, ESGIE and the CRGNB treatment survey study group.

Clin Microbiol Infect. 2018 Oct;24(10):1070-1076. doi: 10.1016/j.cmi.2018.01.015. Epub 2018 Feb 1.

42.

Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy.

Eilertson B, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Evans S, Fowler VG Jr, Bonomo RA, DeHovitz J, Kreiswirth B, van Duin D; Antibacterial Resistance Leadership Group.

Open Forum Infect Dis. 2017 Oct 6;4(4):ofx216. doi: 10.1093/ofid/ofx216. eCollection 2017 Fall.

43.

Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models.

Landersdorfer CB, Wang J, Wirth V, Chen K, Kaye KS, Tsuji BT, Li J, Nation RL.

J Antimicrob Chemother. 2018 Feb 1;73(2):462-468. doi: 10.1093/jac/dkx409.

44.

A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant Enterobacteriaceae.

Henig O, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Marshall S, Rudin SD, Domitrovic TN, Hujer AM, Hujer KM, Doi Y, Evans S, Fowler VG Jr, Bonomo RA, van Duin D, Kaye KS; Antibacterial Resistance Leadership Group.

Open Forum Infect Dis. 2017 Jul 27;4(3):ofx157. doi: 10.1093/ofid/ofx157. eCollection 2017 Summer.

45.

Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.

van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Fowler VG Jr, Paterson DL, Bonomo RA, Evans S; Antibacterial Resistance Leadership Group.

Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.

46.

Bacterial Pneumonia in Older Adults.

Henig O, Kaye KS.

Infect Dis Clin North Am. 2017 Dec;31(4):689-713. doi: 10.1016/j.idc.2017.07.015. Epub 2017 Sep 13. Review.

PMID:
28916385
47.

The impact of obesity and timely antiviral administration on severe influenza outcomes among hospitalized adults.

Segaloff HE, Evans R, Arshad S, Zervos MJ, Archer C, Kaye KS, Martin ET.

J Med Virol. 2018 Feb;90(2):212-218. doi: 10.1002/jmv.24946. Epub 2017 Sep 25.

48.

The Effect of Adding Comorbidities to Current Centers for Disease Control and Prevention Central-Line-Associated Bloodstream Infection Risk-Adjustment Methodology.

Jackson SS, Leekha S, Magder LS, Pineles L, Anderson DJ, Trick WE, Woeltje KF, Kaye KS, Stafford K, Thom K, Lowe TJ, Harris AD.

Infect Control Hosp Epidemiol. 2017 Sep;38(9):1019-1024. doi: 10.1017/ice.2017.129. Epub 2017 Jul 3.

49.

Prevalence of Clostridium difficile infection in acute care hospitals, long-term care facilities, and outpatient clinics: Is Clostridium difficile infection underdiagnosed in long-term care facility patients?

Krishna A, Pervaiz A, Lephart P, Tarabishy N, Varakantam S, Kotecha A, Awali RA, Kaye KS, Chopra T.

Am J Infect Control. 2017 Oct 1;45(10):1157-1159. doi: 10.1016/j.ajic.2017.04.288.

PMID:
28602273
50.

Bathing hospitalized dependent patients with prepackaged disposable washcloths instead of traditional bath basins: A case-crossover study.

Martin ET, Haider S, Palleschi M, Eagle S, Crisostomo DV, Haddox P, Harmon L, Mazur R, Moshos J, Marchaim D, Kaye KS.

Am J Infect Control. 2017 Sep 1;45(9):990-994. doi: 10.1016/j.ajic.2017.03.023. Epub 2017 May 11.

Supplemental Content

Support Center